This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Eli Lilly (LLY) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the most recent trading session, Eli Lilly (LLY) closed at $795.67, indicating a -0.08% shift from the previous trading day.
Novo Nordisk Stock Plunges 18% in a Week: What Should Investors Do?
by Ahan Chakraborty
NVO stock declines after a recent obesity study setback and intense competition from market rivals but offers long-term growth potential.
Company News for Dec 24, 2024
by Zacks Equity Research
Companies In The Article Are: WMT, QCOM, LLY, HMC
Should You Invest in the Fidelity MSCI Health Care Index ETF (FHLC)?
by Zacks Equity Research
Sector ETF report for FHLC
NVO Stock Plunges as Obesity Drug CagriSema Misses Target in Phase III
by Zacks Equity Research
Novo Nordisk stock slumps as the 22.7% weight loss achieved with its next-gen obesity candidate, CagriSema, in a phase III study misses its guidance of 25%.
Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Zacks.com users have recently been watching Lilly (LLY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Lilly's Zepbound Receives FDA Approval for Sleep Apnea
by Zacks Equity Research
FDA approves LLY's obesity drug Zepbound for its second indication, moderate-to-severe obstructive sleep apnea.
Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?
by Zacks Equity Research
Sector ETF report for IHE
LLY Stock Up as FDA Removes Mounjaro, Zepbound From Shortage List
by Zacks Equity Research
Eli Lilly stock gains as the FDA removes tirzepatide drugs from the drug shortage list following a thorough reevaluation.
Merck Enters Obesity Space, Buys Rights to Hansoh's Oral GLP-1 Drug
by Zacks Equity Research
Merck gets exclusive global rights to develop, manufacture and commercialize GLP-1 receptor agonist, HS-10535, from Hansoh Pharma.
Here's Why VKTX Stock Plummeted 18% on Wednesday
by Zacks Equity Research
The selloff in Viking Therapeutics stock comes after some investors raised concerns for the small biotech amid Merck's entry into the obesity space.
Eli Lilly (LLY) Stock Moves -0.05%: What You Should Know
by Zacks Equity Research
In the most recent trading session, Eli Lilly (LLY) closed at $778.62, indicating a -0.05% shift from the previous trading day.
NVS vs. LLY: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
NVS vs. LLY: Which Stock Is the Better Value Option?
NVO to Invest $1.2B in New Rare Disease Drugs Facility in Denmark
by Zacks Equity Research
Novo Nordisk is set to invest $1.2 billion for a new facility in Odense, Denmark, to produce various product types for rare diseases, including haemophilia.
4 Big Drug Stocks That May Continue to Outperform in 2025
by Kinjel Shah
Gilead, Eli Lilly, Vertex Pharmaceuticals and AbbVie have outperformed the industry this year and are likely to see continued momentum in 2025.
ABBV's Acquisition Spree Continues: Buy, Sell or Hold the Stock?
by Kinjel Shah
Investors who own ABBV stock may stay invested as the company has faced its biggest challenge quite well and looks set to return to robust growth next year.
EMA Panel Endorses Lilly's Omvoh for Expanded Use in Crohn's Disease
by Zacks Equity Research
The CHMP's opinion is based on late-stage data, which show that LLY's Omvoh is effective in Crohn's disease patients with or without prior biologic failure.
Eli Lilly Reports Positive Data From Late-Stage Breast Cancer Study
by Zacks Equity Research
Data from a late-stage study shows that LLY's experimental oral drug benefited certain breast cancer patients when used as both a combination and monotherapy.
3 Stocks to Keep an Eye on After Dividend Hike Announcement
by Ritujay Ghosh
Stocks like SYK, LLY and AES recently announced dividend hikes.
Eli Lilly (LLY) Stock Slides as Market Rises: Facts to Know Before You Trade
by Zacks Equity Research
Eli Lilly (LLY) concluded the recent trading session at $796.03, signifying a -0.44% move from its prior day's close.
Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Biogen Stock Declines 21.4% in 3 Months: How to Play the Stock
by Kinjel Shah
Though there is uncertainty about Biogen's sales and profits improving significantly, investors can hold the stock given the potential of its new drugs.
Lilly Announces New $15B Stock Buyback Plan, Ups Dividend by 15%
by Zacks Equity Research
LLY's board approves a new $15B stock buyback plan and announces a 15% increase in its quarterly dividend.
The Zacks Analyst Blog Highlights Eli Lilly, AbbVie, Gilead Sciences, Air T and Fossil Group
by Zacks Equity Research
Eli Lilly, AbbVie, Gilead Sciences, Air T and Fossil Group are included in this Analyst Blog.
Top Stock Reports for Eli Lilly, AbbVie & Gilead Sciences
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), AbbVie Inc. (ABBV) and Gilead Sciences, Inc. (GILD), as well as two micro-cap stocks, Air T, Inc. (AIRT) and Fossil Group, Inc. (FOSL).